ES2340842T3 - Anticuerpos anti-apc no neutralizantes. - Google Patents

Anticuerpos anti-apc no neutralizantes. Download PDF

Info

Publication number
ES2340842T3
ES2340842T3 ES03741459T ES03741459T ES2340842T3 ES 2340842 T3 ES2340842 T3 ES 2340842T3 ES 03741459 T ES03741459 T ES 03741459T ES 03741459 T ES03741459 T ES 03741459T ES 2340842 T3 ES2340842 T3 ES 2340842T3
Authority
ES
Spain
Prior art keywords
apc
present
antibodies
activity
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03741459T
Other languages
English (en)
Inventor
Takaki Koga
Tsukasa Suzuki
Hiroyuki Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30767813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2340842(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2340842T3 publication Critical patent/ES2340842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un anticuerpo contra la proteína C o la proteína C activada, que comprende regiones determinantes de la complementariedad que comprenden las secuencias de aminoácidos de: (a) SEQ ID NOs: 9, 10, 11 (VH), y SEQ ID NOs: 21, 22, 23 (VL), (b) SEQ ID NOs: 31, 32, 33 (VH), y SEQ ID NOs: 24, 25, 34 (VL), o (c) SEQ ID NOs: 15, 16, 17 (VH), y SEQ ID NOs: 27, 28, 29 (VL); en donde el anticuerpo comprende la actividad de (i) potenciar una actividad de la proteína C activada in vivo; (ii) suprimir la inactivación de la proteína C activada in vivo; o (iii) suprimir la inactivación de la proteína C activada, causada por (1) sangre; (2) un inhibidor fisiológico de la proteína C activada; o (3) tanto (1) como (2).
ES03741459T 2002-07-22 2003-07-17 Anticuerpos anti-apc no neutralizantes. Expired - Lifetime ES2340842T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002212582 2002-07-22

Publications (1)

Publication Number Publication Date
ES2340842T3 true ES2340842T3 (es) 2010-06-10

Family

ID=30767813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03741459T Expired - Lifetime ES2340842T3 (es) 2002-07-22 2003-07-17 Anticuerpos anti-apc no neutralizantes.

Country Status (9)

Country Link
US (1) US7517965B2 (es)
EP (1) EP1544214B1 (es)
JP (1) JP4398369B2 (es)
AT (1) ATE460431T1 (es)
AU (1) AU2003281619A1 (es)
DE (1) DE60331665D1 (es)
ES (1) ES2340842T3 (es)
TW (1) TW200407335A (es)
WO (1) WO2004009641A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007101362A (ja) * 2005-10-04 2007-04-19 Hamamatsu Univ School Of Medicine Eiaプレート及びその利用方法
US11046784B2 (en) * 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN103272232B (zh) 2006-06-08 2018-07-24 中外制药株式会社 炎性疾病的预防或治疗药
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
WO2009061918A1 (en) * 2007-11-06 2009-05-14 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
KR101643005B1 (ko) * 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 항nr10 항체 및 그의 이용
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
US20100272640A1 (en) 2009-04-24 2010-10-28 Ozge Alper Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor
KR20130048240A (ko) 2010-07-14 2013-05-09 알퍼 바이오테크, 엘엘씨 Pcbp―1 항원에 대한 모노클로날 항체, 및 그의 용도
EP2925360A4 (en) * 2012-11-29 2016-07-13 Bayer Healthcare Llc MONOCLONAL ANTIBODIES HUMANIZED AGAINST ACTIVATED PROTEIN C AND USES THEREOF
WO2015041310A1 (ja) * 2013-09-20 2015-03-26 中外製薬株式会社 抗プロテインc抗体による出血性疾患の治療
MX2017013141A (es) 2015-04-14 2018-02-21 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
WO2017087391A1 (en) 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
JP6845973B1 (ja) 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11A (es) * 1836-08-10
US1222929A (en) * 1916-08-22 1917-04-17 Brewster & Co Brake mechanism for motor-cars.
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0287028B1 (en) 1987-04-17 1993-07-21 Teijin Limited Method of separating activated human protein c
CA2006684C (en) 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
JP2749619B2 (ja) * 1989-03-10 1998-05-13 エーザイ株式会社 活性化ヒトプロテインcとヒトプロテインcインヒビターの複合体の測定方法および測定試薬
JPH03200066A (ja) * 1989-12-28 1991-09-02 Tosoh Corp 活性化ヒトプロテインcの測定方法
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
DE69333814T2 (de) 1992-03-11 2006-02-02 Powderject Vaccines, Inc., Madison Genetischer impfstoff gegen den immunschwäche virus
WO1995034652A1 (en) * 1994-06-10 1995-12-21 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
JPH1160500A (ja) * 1997-08-11 1999-03-02 Nippon Chem Res Kk 血液凝固異常亢進抑制剤
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JPH11124399A (ja) 1997-10-21 1999-05-11 Eisai Co Ltd プロテインcインヒビターとプロテアーゼの複合体測定用モノクローナル抗体
SE9900431D0 (sv) * 1999-02-09 1999-02-09 Johan Stenflo Monoklonal antikropp
PT1222929E (pt) 2001-01-11 2010-08-18 Life Sciences Res Partners Vzw Método e composição farmacêutica para prevenir e/ou tratar síndrome da resposta inflamatória sistémica
JPWO2004065418A1 (ja) * 2003-01-20 2006-06-29 中外製薬株式会社 抗pci中和抗体

Also Published As

Publication number Publication date
TW200407335A (en) 2004-05-16
WO2004009641A1 (ja) 2004-01-29
JP4398369B2 (ja) 2010-01-13
DE60331665D1 (de) 2010-04-22
US20060121022A1 (en) 2006-06-08
ATE460431T1 (de) 2010-03-15
EP1544214B1 (en) 2010-03-10
EP1544214A1 (en) 2005-06-22
TWI322814B (es) 2010-04-01
AU2003281619A1 (en) 2004-02-09
JPWO2004009641A1 (ja) 2005-11-17
EP1544214A4 (en) 2007-03-28
US7517965B2 (en) 2009-04-14

Similar Documents

Publication Publication Date Title
ES2340842T3 (es) Anticuerpos anti-apc no neutralizantes.
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
DE60108076D1 (de) Protein c derivate
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen